CO5611137A2 - Composiciones de clorhidrato de naltrexona - Google Patents
Composiciones de clorhidrato de naltrexonaInfo
- Publication number
- CO5611137A2 CO5611137A2 CO04090752A CO04090752A CO5611137A2 CO 5611137 A2 CO5611137 A2 CO 5611137A2 CO 04090752 A CO04090752 A CO 04090752A CO 04090752 A CO04090752 A CO 04090752A CO 5611137 A2 CO5611137 A2 CO 5611137A2
- Authority
- CO
- Colombia
- Prior art keywords
- compositions
- naltrexone
- chlorhydrate
- stabilizing
- methods
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1617—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/485—Morphinan derivatives, e.g. morphine, codeine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/167—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface
- A61K9/1676—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface having a drug-free core with discrete complete coating layer containing drug
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2009—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4858—Organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
- A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Emergency Medicine (AREA)
- Inorganic Chemistry (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
Abstract
1.- Una composición farmacéutica de clorhidrato de naltrexona en una cantidad de 20 mg o menos, y un estabilizador que inhibe formación de al menos un producto de degradación de clorhidrato de naltrexona.2.- La composición farmacéutica de la reivindicación 1, en donde dicho estabilizador inhibe la formación de un producto de degradación seleccionado del grupo que consiste de 10-hidroxinaltrexona; 10-cetonaltrexona;2´bisnaltrexona (seudonaltrexona), óxido de 2,2´bisnaltrexona; dióxidos de 2,2´disnaltrexona;aducto de aldol de naltrexona y 10-hidroxinaltrexona, aducto de aldol de naltrexona y 10-cetonaltrexona; naltrexona-N-óxido; 10-hidroxinaltrexona-N-óxido; 10-cetonaltrexona-N-óxido, semiquinonas de naltrexona; peróxidos de radical libre de naltrexona; aducto de aldol denaltrexona; aductos de aldol de naltrexona acoplada en la posición 7,6; aductos de aldol de naltrexona acoplados en la posición 6,5; aducto ligado a éter de naltrexona; aducto ligado a éter de naltrexona y 10-hidroxinaltrexona; aducto ligado a éter de naltrexona y 10-cetonaltrexona;naltrexona deshidrogenada; hidroxi-naltrexona;ceto-naltrexona; sales de estos y mezclas de estos.3.- Una composición farmacéutica que comprende:clorhidrato de naltrexona en una cantidad de 20 mg o menos; yun estabilizador;dicha composición manteniendo al menos aproximadamente 90% de dicho clorhidrato de naltrexona en forma no degradada después de almacenamiento durante un mes a 40±2°C y 75±5% de humedad relativa.4.- La composición farmacéutica de la reivindicación 3, en donde dicha composición mantiene al menos aproximadamente 95% de clorhidrato de naltrexona en forma no degradada después de almacenamiento durante un mes a 40±2°C y 75±5% de unidad relativa.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US36452102P | 2002-03-14 | 2002-03-14 |
Publications (1)
Publication Number | Publication Date |
---|---|
CO5611137A2 true CO5611137A2 (es) | 2006-02-28 |
Family
ID=28041930
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CO04090752A CO5611137A2 (es) | 2002-03-14 | 2004-09-13 | Composiciones de clorhidrato de naltrexona |
Country Status (15)
Country | Link |
---|---|
US (2) | US20030229111A1 (es) |
EP (2) | EP2289492B1 (es) |
JP (2) | JP4683842B2 (es) |
KR (1) | KR20040098660A (es) |
CN (1) | CN1652752A (es) |
AT (1) | ATE510534T1 (es) |
AU (1) | AU2003220290B2 (es) |
BR (1) | BR0308452A (es) |
CA (2) | CA2478558C (es) |
CO (1) | CO5611137A2 (es) |
ES (1) | ES2616981T3 (es) |
IL (1) | IL163911A0 (es) |
MX (1) | MXPA04008772A (es) |
RU (1) | RU2004130441A (es) |
WO (1) | WO2003077867A2 (es) |
Families Citing this family (49)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2314893C (en) | 1997-12-22 | 2005-09-13 | Euro-Celtique, S.A. | Opioid agonist/antagonist combinations |
BR0108379A (pt) | 2000-02-08 | 2002-11-05 | Euro Celtique Sa | Composições de liberação controlada contendo agonista e antagonista opióide, método para a preparação de uma formulação em dosagem de analgésico opióide de liberação controlada com potência analgésica aumentada e sistema de administração através da derme para um analgésico opióide |
DE60238756D1 (de) | 2001-05-11 | 2011-02-10 | Endo Pharmaceuticals Inc | Opioid enthaltende arzneiform gegen missbrauch |
EP1492506B2 (en) | 2002-04-05 | 2016-06-29 | Euro-Celtique S.A. | Matrix for sustained, invariant and independent release of active compounds |
ES2358896T3 (es) * | 2002-08-15 | 2011-05-16 | Euro-Celtique S.A. | Composiciones farmacéuticas que comprenden un analgésico opioide. |
DK2368554T3 (en) | 2003-04-08 | 2015-01-26 | Progenics Pharm Inc | A pharmaceutical composition comprising methylnaltrexone |
TWI347201B (en) * | 2003-04-21 | 2011-08-21 | Euro Celtique Sa | Pharmaceutical products,uses thereof and methods for preparing the same |
JP4758897B2 (ja) * | 2003-09-25 | 2011-08-31 | ユーロ−セルティーク エス.エイ. | ヒドロコドンとナルトレキソンとの併用医薬 |
PT1729730E (pt) * | 2004-03-30 | 2009-04-06 | Euro Celtique Sa | Forma de dosagem resistente às violações que compreende um adsorvente e um agente adverso |
EP1604666A1 (en) | 2004-06-08 | 2005-12-14 | Euro-Celtique S.A. | Opioids for the treatment of the Chronic Obstructive Pulmonary Disease (COPD) |
EP1702558A1 (en) | 2005-02-28 | 2006-09-20 | Euro-Celtique S.A. | Method and device for the assessment of bowel function |
AR057325A1 (es) | 2005-05-25 | 2007-11-28 | Progenics Pharm Inc | Sintesis de (s)-n-metilnaltrexona, composiciones farmaceuticas y usos |
AR057035A1 (es) | 2005-05-25 | 2007-11-14 | Progenics Pharm Inc | SíNTESIS DE (R)-N-METILNALTREXONA, COMPOSICIONES FARMACÉUTICAS Y USOS |
MX2009001294A (es) * | 2006-08-04 | 2009-05-21 | Ethypharm Sa | Granulo y tableta que se desintegra por vía oral que comprende oxicodona. |
TWI489984B (zh) * | 2006-08-04 | 2015-07-01 | Wyeth Corp | 用於非經腸道傳輸化合物之配方及其用途 |
CN101801979A (zh) | 2007-03-29 | 2010-08-11 | 普罗热尼奇制药公司 | (r)-n-溴化甲基纳曲酮的晶体形式及其用途 |
SI2565195T1 (sl) | 2007-03-29 | 2015-09-30 | Wyeth Llc | Periferalni opioidni receptorji in antagonisti in njih uporaba |
CA2865661C (en) | 2007-03-29 | 2016-05-17 | Progenics Pharmaceuticals, Inc. | Peripheral opioid receptor antagonists and uses thereof |
AU2008244936B2 (en) | 2007-04-26 | 2013-02-21 | Toray Industries, Inc. | Stable solid preparation comprising 4,5-epoxymorphinan derivative |
EP2168579B1 (en) * | 2007-05-21 | 2017-10-11 | Toray Industries, Inc. | Oral preparation comprising specific organic acid, and method for improvement in dissolution property and chemical stability of oral preparation |
EP2065038A1 (en) * | 2007-11-30 | 2009-06-03 | Pharnext | New therapeutic approaches for treating Charcot-Marie-Tooth disease |
JP5358587B2 (ja) | 2008-02-06 | 2013-12-04 | プロジェニックス・ファーマシューティカルス・インコーポレイテッド | (r),(r)−2,2’−ビス−メチルナルトレキソンの製造及び用途 |
US20110250278A1 (en) | 2008-07-01 | 2011-10-13 | University Of Chicago | Particles containing an opioid receptor antagonist and methods of use |
CN101658489B (zh) * | 2008-08-27 | 2011-11-23 | 海南四环心脑血管药物研究院有限公司 | 一种盐酸纳美芬注射液及其制备方法 |
CA2676881C (en) | 2008-09-30 | 2017-04-25 | Wyeth | Peripheral opioid receptor antagonists and uses thereof |
KR101682963B1 (ko) | 2008-10-24 | 2016-12-06 | 도레이 카부시키가이샤 | 4,5-에폭시모르피난 유도체를 함유하는 안정한 정제 |
MX347106B (es) | 2009-03-10 | 2017-04-12 | Euro-Celtique S A * | Coposiciones farmacéuticas de liberación inmediata que comprenden oxicodona y naloxona. |
US9393241B2 (en) | 2009-06-02 | 2016-07-19 | Pharnext | Compositions for treating CMT and related disorders |
EP2263665A1 (en) | 2009-06-02 | 2010-12-22 | Pharnext | New compositions for treating CMT and related disorders |
WO2011052499A1 (ja) * | 2009-10-28 | 2011-05-05 | 第一三共株式会社 | 貯蔵安定性が改善された医薬組成物 |
AR080491A1 (es) | 2010-03-11 | 2012-04-11 | Wyeth Llc | Formulaciones orales y sales lipofilicas de metilnaltrexona |
CN103002882B (zh) | 2010-05-10 | 2016-03-02 | 欧洲凯尔特公司 | 不含活性剂之颗粒及包含其之片剂的制备 |
US9901540B2 (en) | 2010-05-10 | 2018-02-27 | Euro-Celtique S.A. | Combination of active loaded granules with additional actives |
TWI560170B (en) * | 2011-12-06 | 2016-12-01 | Lundbeck & Co As H | Process for recovery of nalmefene hydrochloride |
CA2795324C (en) * | 2012-11-09 | 2015-07-14 | Purdue Pharma | Pharmaceutical compositions comprising hydromorphone and naloxone |
LT3003268T (lt) * | 2013-06-05 | 2018-12-10 | Pharnext | Stabilūs peroraliniai tirpalai, skirti kompleksiniam aktyviam farmaciniam ingredientui (api) |
CA2918004C (en) | 2013-07-23 | 2018-11-20 | Euro-Celtique S.A. | A combination of oxycodone and naloxone for use in treating pain in patients suffering from pain and a disease resulting in intestinal dysbiosis and/or increasing the risk for intestinal bacterial translocation |
KR102194174B1 (ko) | 2013-11-13 | 2020-12-23 | 유로-셀티큐 에스.에이. | 통증 및 오피오이드 장 기능장애 증후군의 치료를 위한 히드로모르폰 및 날록손 |
CN105582011A (zh) * | 2014-10-24 | 2016-05-18 | 江苏国丹生物制药有限公司 | 溴甲纳曲酮固体组合物及其制备方法 |
CA2999509A1 (en) * | 2015-09-24 | 2017-03-30 | Pain Therapeutics, Inc. | Crystalline salts of naloxone and naltrexone |
US10383870B2 (en) | 2016-06-10 | 2019-08-20 | Pharnext | Early treatment of CMT disease |
CN110114457A (zh) * | 2016-10-18 | 2019-08-09 | 安思雅公司 | 产生去甲阿片类和nal-阿片类苄基异喹啉生物碱的方法 |
US11185540B2 (en) * | 2017-04-12 | 2021-11-30 | Pardon My Scotch Llc. | Extended release compositions of opioid antagonists and phosphodiesterase 5 inhibitors |
US10799496B2 (en) | 2018-07-13 | 2020-10-13 | Alkermes Pharma Ireland Limited | Naphthylenyl compounds for long-acting injectable compositions and related methods |
US10807995B2 (en) | 2018-07-13 | 2020-10-20 | Alkermes Pharma Ireland Limited | Thienothiophene compounds for long-acting injectable compositions and related methods |
US10975099B2 (en) | 2018-11-05 | 2021-04-13 | Alkermes Pharma Ireland Limited | Thiophene compounds for long-acting injectable compositions and related methods |
BR112022000218A2 (pt) | 2019-07-10 | 2022-02-22 | Intas Pharmaceuticals Ltd | Composição farmacêutica estável livre de lactose e processo para a preparação de uma composição farmacêutica estável livre de lactose |
JPWO2021100728A1 (es) * | 2019-11-20 | 2021-05-27 | ||
WO2022173402A1 (en) * | 2021-02-09 | 2022-08-18 | Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi | A film coated tablet comprising naltrexone hydrochloride |
Family Cites Families (23)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3332950A (en) | 1963-03-23 | 1967-07-25 | Endo Lab | 14-hydroxydihydronormorphinone derivatives |
US4587118A (en) * | 1981-07-15 | 1986-05-06 | Key Pharmaceuticals, Inc. | Dry sustained release theophylline oral formulation |
FR2609632B1 (fr) * | 1987-01-21 | 1991-03-29 | Shelly Marc | Nouvelle application therapeutique de la 17-(cyclopropylmethyl)-4,5-epoxy-3,14-dihydroxymorphinon-6-one et les compositions pharmaceutiques destinees a cet usage |
US4816586A (en) * | 1987-07-29 | 1989-03-28 | Regents Of The University Of Minnesota | Delta opioid receptor antagonists |
US5994392A (en) * | 1988-02-26 | 1999-11-30 | Neuromedica, Inc. | Antipsychotic prodrugs comprising an antipsychotic agent coupled to an unsaturated fatty acid |
JP3456211B2 (ja) * | 1991-09-27 | 2003-10-14 | 藤沢薬品工業株式会社 | 持続性製剤 |
US6271239B1 (en) * | 1992-04-13 | 2001-08-07 | Regents Of The University Of Minnesota | Delta opioid receptor-selective benzylidene-substituted morphinans |
US5512578A (en) | 1992-09-21 | 1996-04-30 | Albert Einstein College Of Medicine Of Yeshiva University, A Division Of Yeshiva University | Method of simultaneously enhancing analgesic potency and attenuating dependence liability caused by exogenous and endogenous opiod agonists |
US5472943A (en) | 1992-09-21 | 1995-12-05 | Albert Einstein College Of Medicine Of Yeshiva University, | Method of simultaneously enhancing analgesic potency and attenuating dependence liability caused by morphine and other opioid agonists |
US5580876A (en) | 1992-09-21 | 1996-12-03 | Albert Einstein College Of Medicine Of Yeshiva University, A Division Of Yeshiva University | Method of simultaneously enhancing analgesic potency and attenuating dependence liability caused by morphine and other bimodally-acting opioid agonists |
US5697282A (en) * | 1994-03-15 | 1997-12-16 | Schuller International, Inc. | Apparatus for and method of forming large diameter duct with liner and the product formed thereby |
DK0914097T3 (da) * | 1996-03-12 | 2002-04-29 | Alza Corp | Sammensætning og doseringsform omfattende opioid antagonist |
SK282549B6 (sk) | 1997-02-14 | 2002-10-08 | G�decke Aktiengesellschaft | Spôsob stabilizácie naloxonhydrochloridu |
US5980882A (en) * | 1997-04-16 | 1999-11-09 | Medeva Pharmaceuticals Manufacturing | Drug-resin complexes stabilized by chelating agents |
CA2314893C (en) * | 1997-12-22 | 2005-09-13 | Euro-Celtique, S.A. | Opioid agonist/antagonist combinations |
US6166211A (en) * | 1999-03-19 | 2000-12-26 | Endo Pharmaceuticals, Inc. | Sequential benzylic oxidations of the naloxone ring system |
GB9908921D0 (en) * | 1999-04-19 | 1999-06-16 | Britannia Pharmaceuticals Ltd | Spray dispenser for opiod antagonists |
US6071918A (en) * | 1999-07-21 | 2000-06-06 | Dupont Pharmaceuticals Company | Combination of an opioid antagonist and a selective serotonin reuptake inhibitor for treatment of alcoholism and alcohol dependence |
BR0108379A (pt) | 2000-02-08 | 2002-11-05 | Euro Celtique Sa | Composições de liberação controlada contendo agonista e antagonista opióide, método para a preparação de uma formulação em dosagem de analgésico opióide de liberação controlada com potência analgésica aumentada e sistema de administração através da derme para um analgésico opióide |
EP1284736A2 (en) * | 2000-05-05 | 2003-02-26 | Pain Therapeutics, Inc. | Opioid antagonist compositions and dosage forms |
HUP0401191A3 (en) * | 2001-08-06 | 2006-11-28 | Euro Celtique Sa | Opioid agonist formulations with releasable and sequestered antagonist and process for their preparation |
US7332182B2 (en) * | 2001-08-06 | 2008-02-19 | Purdue Pharma L.P. | Pharmaceutical formulation containing opioid agonist, opioid antagonist and irritant |
TWI347201B (en) * | 2003-04-21 | 2011-08-21 | Euro Celtique Sa | Pharmaceutical products,uses thereof and methods for preparing the same |
-
2003
- 2003-03-14 CA CA2478558A patent/CA2478558C/en not_active Expired - Lifetime
- 2003-03-14 IL IL16391103A patent/IL163911A0/xx unknown
- 2003-03-14 AT AT03716588T patent/ATE510534T1/de not_active IP Right Cessation
- 2003-03-14 WO PCT/US2003/007932 patent/WO2003077867A2/en active IP Right Grant
- 2003-03-14 AU AU2003220290A patent/AU2003220290B2/en not_active Expired
- 2003-03-14 KR KR10-2004-7013905A patent/KR20040098660A/ko not_active Application Discontinuation
- 2003-03-14 EP EP10010921.4A patent/EP2289492B1/en not_active Expired - Lifetime
- 2003-03-14 RU RU2004130441/15A patent/RU2004130441A/ru not_active Application Discontinuation
- 2003-03-14 JP JP2003575921A patent/JP4683842B2/ja not_active Expired - Lifetime
- 2003-03-14 EP EP03716588A patent/EP1482912B1/en not_active Expired - Lifetime
- 2003-03-14 CA CA2748620A patent/CA2748620C/en not_active Expired - Lifetime
- 2003-03-14 MX MXPA04008772A patent/MXPA04008772A/es unknown
- 2003-03-14 ES ES10010921.4T patent/ES2616981T3/es not_active Expired - Lifetime
- 2003-03-14 BR BRPI0308452-3A patent/BR0308452A/pt not_active IP Right Cessation
- 2003-03-14 CN CNA038103737A patent/CN1652752A/zh active Pending
- 2003-03-14 US US10/389,238 patent/US20030229111A1/en not_active Abandoned
-
2004
- 2004-09-13 CO CO04090752A patent/CO5611137A2/es not_active Application Discontinuation
-
2009
- 2009-02-12 JP JP2009029529A patent/JP5291483B2/ja not_active Expired - Fee Related
-
2016
- 2016-10-20 US US15/298,483 patent/US20170100337A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
US20030229111A1 (en) | 2003-12-11 |
IL163911A0 (en) | 2005-12-18 |
ES2616981T3 (es) | 2017-06-15 |
EP1482912B1 (en) | 2011-05-25 |
CA2478558C (en) | 2012-09-11 |
BR0308452A (pt) | 2006-06-06 |
ATE510534T1 (de) | 2011-06-15 |
JP2009143948A (ja) | 2009-07-02 |
CA2748620C (en) | 2014-03-11 |
EP1482912A4 (en) | 2006-11-15 |
WO2003077867A3 (en) | 2004-09-02 |
US20170100337A1 (en) | 2017-04-13 |
JP4683842B2 (ja) | 2011-05-18 |
RU2004130441A (ru) | 2005-05-20 |
EP2289492A3 (en) | 2011-12-21 |
CA2748620A1 (en) | 2003-09-25 |
KR20040098660A (ko) | 2004-11-20 |
MXPA04008772A (es) | 2004-12-06 |
JP5291483B2 (ja) | 2013-09-18 |
EP2289492B1 (en) | 2016-12-07 |
CA2478558A1 (en) | 2003-09-25 |
EP1482912A2 (en) | 2004-12-08 |
AU2003220290A1 (en) | 2003-09-29 |
EP2289492A2 (en) | 2011-03-02 |
JP2005531515A (ja) | 2005-10-20 |
AU2003220290B2 (en) | 2007-06-14 |
WO2003077867A2 (en) | 2003-09-25 |
CN1652752A (zh) | 2005-08-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CO5611137A2 (es) | Composiciones de clorhidrato de naltrexona | |
DE60311307D1 (de) | Shampoo-zusammensetzungen | |
FR2842416B1 (fr) | Composition cosmetique | |
NO20062860L (no) | Sammensetning og fremgangsmate for styrking av biologisk tilgjengelighet | |
HUP0401190A3 (en) | Treatment of nail infections using no generating compositions | |
ATE367143T1 (de) | Schweisshemmende oder deodorierende zusammensetzungen | |
ITMI20021228A1 (it) | Composizioni di poliuretani reticolabili | |
DE60225040D1 (de) | Montelukast-granulatformulierung | |
BR0307058A (pt) | N-óxidos de derivados de n-fenil-2-pirimidina-amina | |
DE10393374D2 (de) | Zusammensetzung | |
DE60333311D1 (de) | Kosmetische zusammensetzung | |
SE0500163L (sv) | Sammansättning | |
ATE471931T1 (de) | Verbindungen, zusammensetzungen und verfahren | |
DE60304928D1 (de) | Silica-gefüllte Elastomerenzusammensetzung | |
DE60316636D1 (de) | Mittels Additionsreaktion härtbare Organopolysiloxan-Zusammensetzungen | |
DE60316954D1 (de) | Shampoozusammensetzungen | |
DE60237109D1 (de) | Rbesserte transistoreigenschaften | |
DE60234592D1 (de) | Wässrige zusammensetzung | |
DE60326190D1 (de) | des Körpers | |
BR0206044B1 (pt) | Composição alvejante | |
DK1492501T3 (da) | Fremgangsmåder med anvendelse af lamellare legemer til terapeutiske formål | |
DE60326900D1 (de) | Duftstoff-Zusammensetzung | |
IS7488A (is) | Dreyfasamsetning í föstu formi | |
ATE326208T1 (de) | Haarbehandlungszusammensetzungen | |
NO20020524L (no) | Stabiliserte organisk-peroksid sammensetninger |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FA | Application withdrawn |